Apricus Biosciences Announces Allowance of Israeli Patent, Expanding Its Patent Portfolio for the Topical Treatment of Premature Ejaculation

SAN DIEGO, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the Israeli Patent Office recently issued a Notice of Allowance to grant a patent for the Company's development of a topical cream utilizing vasoactive prostaglandin E to treat premature ejaculation ("PE"). When issued, the patent, entitled, "Compositions and Methods for the Treatment of Premature Ejaculation," will provide Israeli patent protection until March 2024. It is one in a series of issued patents and pending applications that Apricus Bio owns in the male sexual dysfunction field utilizing its proprietary NexACT® technology, which includes its Vitaros® product to treat erectile dysfunction ("ED"), among others in research and development.